| Nov 20 |
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
|
| Nov 8 |
Aptose Biosciences GAAP EPS of -$0.37 beats by $0.27
|
| Nov 8 |
Aptose Reports Results for the Third Quarter 2024
|
| Sep 5 |
Aptose Announces Results from Special Meeting of Shareholders
|
| Sep 3 |
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
|
| Sep 3 |
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday
|
| Sep 2 |
Aptose Biosciences secures funds for AML treatment development
|
| Aug 30 |
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
|
| Aug 15 |
Aptose Announces Adjournment of its Special Meeting of Shareholders
|
| Aug 8 |
Aptose Biosciences GAAP EPS of -$0.43 beats by $0.15
|
